Precocious oocyte maturation is induced by an inhibitor of cAMP-dependent protein kinase in the intact golden hamster.
The purpose of this investigation was to determine if precocious oocyte maturation could be induced by modulating ovarian cAMP-dependent protein kinase (PKA) or protein kinase C (PKC) signal transduction pathways in the intact hamster. The following inhibitors and stimulators were injected into the ovarian bursal cavity of the anesthetized hamster: N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), a relatively selective inhibitor of PKA phosphorylations; a structurally related compound, H-7, a less potent and selective inhibitor used to alter PKA and PKC pathways; phorbol 12, 13-didecanoate (PDD beta), an active stimulator of PKC and the inactive analog, 4 alpha-phorbol 12, 13-didecanoate (PDD alpha); and GF109203x, a potent and selective inhibitor of PKC phosphorylations. The experimental design was to inject the modulator into the bursal cavity of one ovary and control solution of diluent or inactive compound into the contralateral bursal cavity. After 1 hr oocytes were collected and evaluated microscopically for the presence or absence of a germinal vesicle. Only oocytes recovered from H-89 treated ovaries (> 50 microM) showed significantly greater frequency of meiotic resumption. Exposure of ovaries to H-7 (< or = 150 microM), PDD beta (< or = 100 microM), or GF109203x (< or = 100 microM) did not significantly affect oocyte maturation state. These results suggest that ovarian protein phosphorylations carried out by PKA are necessary for the maintenance of oocyte meiotic arrest in situ.
Rose-Hellekant
T A
TA
Department of Animal Health and Biomedical Sciences, University of Wisconsin-Madison 53706, USA.
Bavister
B D
BD
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000494:pharmacology*; D000818:Animals; D006224:Cricetinae; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors*; D005260:Female; D007211:Indoles / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology*; D008301:Maleimides / Q000494:pharmacology*; D008647:Mesocricetus; D009865:Oocytes / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D010703:Phorbol Esters / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D015398:Signal Transduction; D013449:Sulfonamides
D007211:Indoles; D007546:Isoquinolines; D008301:Maleimides; D010703:Phorbol Esters; D013449:Sulfonamides; C008876:phorbol-12,13-didecanoate; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; C070515:bisindolylmaleimide I; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide